Envisagenics focuses on discovering and developing cancer therapeutics that arise from alternative RNA splicing. The company’s approach to target selection is explicitly inspired by the splice-modulating success of Spinraza. It was founded by scientists from Cold Spring Harbor Laboratory. Co-founders include Maria Luisa Pineda and Martin Akerman. The startup has just completed a financing event to advance its drug programs. The announced raise is intended to support development of cancer drug targets created by alternative RNA splicing. Envisagenics is a New York City–based biotechnology company that uses artificial intelligence and high-performance computing to discover and develop novel RNA splicing therapeutics. Its principal proprietary technology, the SpliceCore® discovery platform, re‑envisions the human genome through an exon‑centric approach combined with machine learning and HPC. SpliceCore’s database comprises approximately seven million RNA splicing events and has been commercially validated by multiple biopharma leaders. The company is led by co‑founder and CEO Maria Luisa Pineda, Ph.D., and co‑founder and CTO Martin Akerman, Ph.D. Envisagenics secured a Series A financing of undisclosed amount led by Red Cell Partners. It intends to use the funds to scale its drug discovery platform and expand biopharmaceutical partnerships. Envisagenics is a New York-based company that integrates artificial intelligence with RNA therapeutics to develop cures for diseases caused by splicing errors. The company targets hundreds of diseases driven by RNA splicing defects. Envisagenics was named one of four global winners of M12’s Innovate.AI competition at the Collision Conference. Winners of each region were awarded a total of $1M in venture funding from M12 and its partners and up to $500K in Azure credits. The announcement was made by M12 alongside Madrona Venture Group, Notion Capital and Vertex Ventures. Envisagenics is an early drug discovery company that applies artificial intelligence to patient genetic sequences to discover new therapies. Its proprietary cloud-based discovery platform, SpliceCore™, uses machine learning to prioritize new drug target candidates from patients' RNA. The company focuses on RNA splicing, the cellular process that edits RNA to produce functional proteins. Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory and is based in New York, NY. Led by co-founder and CEO Dr. Maria Luisa Pineda, the company raised $2.25m in seed funding. The seed proceeds are intended to advance its AI-driven discovery work using SpliceCore™.

Total raised

$28M

Funding rounds

4

Latest round

Series B

Latest activity

Jun 2024